Pipetman Ultra U100

... and data management system ,RADIANCE is ... needs of data management systems (DMS), and ... of STAT analyzer systems., ,The RADIANCE software ... for both STAT analyzers and hospital and ...

... syngo Dynamics network is ... and archiving system using evidence-based ... of clinical procedures. It has ... practical reality for hospital echocardiography ...

... AXIOM Artis dTC is a versatile ... the cardiology department from preparation to ... interventional procedures. With AXIOM Artis dTC, your ... the cardiology department that leaves you free ...

... ACUSON Cypress cardiovascular system ... worlds first portable, high-performance transesophageal ... highly miniaturized, all-digital, phased array ... studies and outstanding images, even ...

Medicine Products:

RADIANCE syngoDynamics AXIOM Artis dTC ACUSON Cypress cardiovascular system PLUS

(Date:12/6/2009)... advised to avoid oysters harvested from San Antonio Bay ... The U.S. Food and Drug Administration is advising consumers ... Bay on or after Nov. 16 due to reports ... oysters harvested from this area, which is located on ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ,, The FDA, along with the ...

(Date:12/6/2009)... that the loss of a key segment of DNA can ... to show that this kind of genetic alteration can cause ... , The study, led by Dr Sadaf Farooqi from the ... Trust Sanger Institute, looked at 300 children with severe obesity. ... types of mutation known as copy number variants (CNVs). CNVs ...

(Date:12/6/2009)... feline DNA in virus , , SUNDAY, Dec. 6 (HealthDay News) ... be found in a tiger that lived thousands or millions ... the virus took on a bit of a tiger,s genetic ... in the virus to this day. That tiger, in fact, ... the virus that ultimately led to its infection of humans. ...

(Date:12/6/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... pivotal Phase 2b 003-A1 study, known as the ... heavily pre-treated relapsed and refractory multiple myeloma patients. ... Joint Symposium at the 51st annual meeting of ... Orleans. Enrollment in this trial is complete (n=269), ...

(Date:12/6/2009)... Dec. 6 Blood clotting, or coagulation, ... when a blood vessel is injured. Sometimes, however, ... an obvious injury or do not dissolve naturally, ... today at the 51st Annual Meeting of the ... of using the anticoagulants aspirin and heparin with ...

Breaking Medicine News(10 mins):Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2 Health News:Genetic studies reveal new causes of severe obesity in childhood 2 Health News:AIDS May Date Back to Ancient Tiger 2 Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2 Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3 Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4 Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6 Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7

[0] FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters [1] Genetic studies reveal new causes of severe obesity in childhood [0] AIDS May Date Back to Ancient Tiger [1] Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability [1] Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages

... who do drop risk of premature birth, smaller babies ... who quit smoking before the 15th week of pregnancy ... babies to that of nonsmoking women, a new study ... the risk of miscarriage, ectopic pregnancy, premature birth, small ...

... Hancock Medical Center for Making Quality of Care "No. 1 Priority" ... ... in Bay Saint Louis, Miss., was named Mississippi Hospital of the ... Awards on March 2. The hospital, a QHR management client ...

... Pregis Corporation, a leading international manufacturer, marketer, and ... today announced its 2008 fourth quarter and full year ... generated net sales of $219.6 million, a decrease of ... fourth quarter of 2007. Excluding incremental revenue from ...

... Study finds it suppresses enzyme vital to tumor growth , , ... combat AIDS may also help slow the spread of a ... , A study published in the current issue of the ... suppresses the enzyme telomerase. Telomerase activity appears to be essential ...

... Health and Safety and Pharmaceutical Innovation First ... Pharmaceutical Association (GPhA) released the following statement ... Jaeger regarding the bipartisan Senate introduction of ... Medicine Act.""Momentum is skyrocketing for biogenerics legislation ...

... common drugs, study finds , , THURSDAY, March 26 (HealthDay ... can be triggered by some commonly used heart medications, ... the condition followed injections of adrenaline or dobutamine, according ... issue of the Journal of the American College ...

Newly Pregnant Smokers Have a 15-Week Window to Quit QHR Management Client Hancock Medical Center Named Mississippi Hospital of the Year Pregis Announces Fourth Quarter and Full Year 2008 Financial Results AIDS Drug Slows Spread of Deadly Childhood Brain Cancer GPhA Statement on the Introduction of the Bipartisan Senate Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act'What Causes Mystery Heart Condition?

(Date:12/7/2009)... /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd.,announced today ... data for TG-0054,the Company,s chemokine receptor CXCR4 ... at the ASH Annual Meeting held in ... 8, 2009. , ... will be presented. In this randomized,double-blind, placebo-controlled, ...

(Date:12/7/2009)... RAPIDS, Mich., Dec. 7 On December ... on its eight-story, $178 million, 240,000 square foot ... and scientific opportunity both for VAI and West ... the more than $1 billion investment in infrastructure ... When operating at capacity, the expansion will support ...

(Date:12/7/2009)... ,, 60 people, males and females, ... antibodies generated by the vaccine specifically identified several ... BiondVax,s CEO Dr. Ron Babecoff: "This is ... realization of the Company,s vision of ensuring protection ... , BiondVax Pharmaceuticals Ltd. (TASE: ...

Breaking Medicine Technology:TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2 Van Andel Institute Cuts Ribbon on $178 Million Expansion 2 Van Andel Institute Cuts Ribbon on $178 Million Expansion 3 Van Andel Institute Cuts Ribbon on $178 Million Expansion 4 Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2 Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3 Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4 Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5 XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 1 XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 2 XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 3 New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 1 New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 2 New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 3 New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 4 New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 5 New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 6 First and Only Weaning Product Based on 100 25 Non Allergenic Amino Acids Specifically Designed for Children With Cows Milk Protein Allergy and Multip 48577 1 First and Only Weaning Product Based on 100 25 Non Allergenic Amino Acids Specifically Designed for Children With Cows Milk Protein Allergy and Multip 48577 2 First and Only Weaning Product Based on 100 25 Non Allergenic Amino Acids Specifically Designed for Children With Cows Milk Protein Allergy and Multip 48577 3

[0] TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting [0] Van Andel Institute Cuts Ribbon on $178 Million Expansion [0] Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine

Products	Pipetman Ultra U100
Company	Gilson, Inc
Item	Pipetman Ultra U100
Features
Description	Pipetman Ultra is a fully adjustable, air-displacement pipette with a patented multifunctional electronic display. It is the latest member of the Pipetman family, sharing many of the same characteristics: robustness, accuracy, and precision. We also added a number of features based on feedback from our customers. Eight models cover the full range of volumes from 0.2 L to 10 mL.
Info	Gilson, Inc Customer Service: (800) 445-7661 Web site: http://www.gilson.com/